150323-21-0

Basic information

• Product Name: (-)-(2S,4R)-7-benzyl-2-hydroxymethyl-5-oxo-pyrrolidine
• Synonyms: (-)-(2S,4R)-7-benzyl-2-hydroxymethyl-5-oxo-pyrrolidine
• CAS NO: 150323-21-0
• Molecular Weight: 205.257
• Mol File: 150323-21-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (-)-(2S,4R)-7-benzyl-2-hydroxymethyl-5-oxo-pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-(2S,4R)-7-benzyl-2-hydroxymethyl-5-oxo-pyrrolidine(150323-21-0)
• EPA Substance Registry System: (-)-(2S,4R)-7-benzyl-2-hydroxymethyl-5-oxo-pyrrolidine(150323-21-0)

Safety Data

• Hazardous Substances Data: 150323-21-0(Hazardous Substances Data)

Upstream product

• 134037-88-0 (+)-(2R,5S,7R)-1-aza-3-oxa-2-phenyl-7-(phenylmethyl)bicyclo<3.3.0>octan-8-one 
• 129413-78-1 5(S)-((t-butyl-dimethyl-silyloxy)methyl)-3(R)-phenylmethyl-N-BOC-2-pyrrolidinone 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 17342-08-4 (S)-Pyroglutaminol 
• 166765-32-8 (+)-(2R,5S,7S)-7-phenylmethyl-7-ethoxycarbonyl-2-phenyl-1-aza-3-oxa-bicyclo<3.3.0>octan-8-one 
• 176243-48-4 ((+)-2R,5S,7S)-7-phenylmethyl-7-carboxyl-2-phenyl-1-aza-3-oxa-bicyclo<3.3.0>octan-8-one 
• 254909-27-8 (2R,5S)-7-ethoxycarbonyl-2-phenyl-1-aza-3-oxa-lbicyclo<3.3.0>octan-8-one 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 127949-75-1 (2S)-4-benzylpyroglutamic acid 

Relevant articles and documents

Functionalised pyrrolidinones derived from (S)-pyroglutamic acid

The generation of the lactam enolate derived from bicyclic lactams 2a-c, prepared from (S)-pyroglutamic acid 1a, and subsequent reaction with a range of electrophiles, is reported. Exo-diastereoselectivity is generally favoured. The deprotection of some of these adducts to give functionalised hydroxymethylpyrrolidinones is readily achieved by simple hemiaminal ether cleavage under acidic conditions.

HIV protease inhibitors useful for the treatment of AIDS

Compounds of formula STR1 where R1 and R2 are independently hydrogen or optionally-substituted C1-4 alkyl or aryl, or R1 and R2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of treating infection by HIV are also described.